Olaparib shows promise in treating ovarian cancer, even without BRCA mutations

August 21, 2011 in Cancer

The PARP inhibitor, olaparib, that has shown promise in women with an inherited mutation in their BRCA1 or BRCA2 gene (accounting for about 5-10% of breast and ovarian cancer cases), has, for the first time, been shown to reduce the size of tumours in a much wider group of ovarian cancer patients without these BRCA gene mutations. The findings, published Online First in The Lancet Oncology, highlight the potential of olaparib to treat patients with more common sporadic (non-hereditary) tumours and could offer a new treatment option for one of the most deadly cancers in women.

"Olaparib represents a promising therapeutic option for patients with this aggressive malignant disease for whom treatment options are limited to toxic chemotherapies", explains lead author Karen Gelmon from the BC Cancer Agency, Vancouver, Canada.

Olaparib works by blocking the activity of a protein called Poly (ADP ribose) polymerase (PARP). Both PARP and BRCA proteins are involved in DNA repair. Inhibiting PARP in a tumour that already lacks a BRCA gene prevents from repairing their DNA (enhancing the effectiveness of DNA-damaging ) and causes them to die—a process known as synthetic lethality.*

Until now, whether olaparib could also be effective in a broader group of sporadic breast and ovarian cancers that might share similar DNA repair deficiencies, such as triple-negative breast cancer and high-grade serous ovarian cancer, was not known.

The phase 2 trial was designed to evaluate the drug's effectiveness in the treatment of breast and ovarian cancer without mutations. Between July, 2008, and September, 2009, 92 patients (65 with ovarian cancer and 26 breast cancer) were given olaparib 400 mg twice daily for 4 weeks, and classified according to their BRCA1 and BRCA2 mutation status.

Among women with ovarian cancer, 41% with BRCA mutations showed a substantial shrinkage in the size of their tumours compared with 24% of patients without mutations. None of the patients with breast cancer had an objective response.

Olaparib was generally well tolerated and most side effects were mild, including fatigue, nausea, vomiting, and decreased appetite. The authors conclude: "New treatments targeting mechanisms seem to provide new hope for treatment of ovarian cancer."

In a Comment, Melinda Telli from Stanford University School of Medicine, California, USA discusses the potential of this new class of genetically-targeted drugs and remarks: "For the first time, activity of a PARP inhibitor as monotherapy in women with advanced high-grade serous ovarian cancer who do not have a germline or BRCA2 mutation [has been shown]. This finding not only suggests new therapeutic possibilities for women with this aggressive type of , but also importantly confirms the hypothesis that subpopulations of patients with common sporadic tumours can be targeted effectively with PARP inhibitor therapy."

More information: Paper online: www.thelancet.com/… 4-5/abstract

Provided by Lancet

not rated yet  

Rank not rated yet
Relevant PhysicsForums posts

More news stories

Small cancer risk following CT scans in childhood and adolescence confirmed

The gap between life expectancy in patients with a mental illness and the general population has widened since 1985 and efforts to reduce this gap should focus on improving physical health, suggest researchers in a paper ...

Cancer created 10 hours ago | popularity not rated yet | comments 0

Changing cancer's environment to halt its spread

By studying the roles two proteins, thrombospondin-1 and prosaposin, play in discouraging cancer metastasis, a trans-Atlantic research team has identified a five-amino acid fragment of prosaposin that significantly reduces ...

Cancer created 11 hours ago | popularity not rated yet | comments 0

Novel RNA-based classification system for colorectal cancer

A novel transcriptome-based classification of colon cancer that improves the current disease stratification based on clinicopathological variables and common DNA markers is presented in a study published in PLOS Medicine this w ...

Cancer created 11 hours ago | popularity not rated yet | comments 0

Low radiation scans help identify cancer in earliest stages

A study of veterans at high risk for developing lung cancer shows that low-dose computed tomography (LDCT) can be highly effective in helping clinicians spot tiny lung nodules which, in a small number of patients, may indicate ...

Cancer created 13 hours ago | popularity not rated yet | comments 0

Poliovirus vaccine trial shows early promise for recurrent glioblastoma

An attack on glioblastoma brain tumor cells that uses a modified poliovirus is showing encouraging results in an early study to establish the proper dose level, researchers at Duke Cancer Institute report.

Cancer created 15 hours ago | popularity not rated yet | comments 0


Phthalates: Study links chemicals widely found in plastics, processed food to elevated blood pressure in children, teens

Plastic additives known as phthalates (pronounced THAL-ates) are odorless, colorless and just about everywhere: They turn up in flooring, plastic cups, beach balls, plastic wrap, intravenous tubing and—according to the ...

If you can remember it, you can remember it wrong

(Medical Xpress)—Native peoples in regions where cameras are uncommon sometimes react with caution when their picture is taken. The fear that something must have been stolen from them to create the photo ...

B vitamins could delay dementia

(Medical Xpress)—Despite spending billions of dollars on research and development, drug companies have been unable to come up with effective treatments for dementia and Alzheimer's Disease (AD). Now, A. ...

Insight into the dazzling impact of insulin in cells

Australian scientists have charted the path of insulin action in cells in precise detail like never before. This provides a comprehensive blueprint for understanding what goes wrong in diabetes.

New sleeping pill poised to hit US markets

An experimental sleeping pill from US drug company Merck is effective at helping people fall and stay asleep, according to reviewers at the US Food and Drug Administration, which could soon approve the new drug.

Reducing caloric intake delays nerve cell loss

Activating an enzyme known to play a role in the anti-aging benefits of calorie restriction delays the loss of brain cells and preserves cognitive function in mice, according to a study published in the May ...